NCT05107180

Brief Summary

detect risk of suicide among patient with substance use disorder

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Dec 2021

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 25, 2021

Completed
10 days until next milestone

First Posted

Study publicly available on registry

November 4, 2021

Completed
27 days until next milestone

Study Start

First participant enrolled

December 1, 2021

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2021

Completed
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2023

Completed
Last Updated

November 10, 2021

Status Verified

October 1, 2021

Enrollment Period

Same day

First QC Date

October 25, 2021

Last Update Submit

November 9, 2021

Conditions

Substance Use Disorders

Outcome Measures

Primary Outcomes (2)

  • Prevelance of suicide and suicide tendancy in patients with substance use disorders.

    observation and study of prevelance of suicide among patient with substance use disorders

    6 months

  • Detect risk factors for suicide and in patients with substance use disorder.

    observation of patient

    6 months

Interventions

drug screenDIAGNOSTIC_TEST

urine sample

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

patient with substance use disorder

You may qualify if:

  • Patients fulfilling diagnostic criteria of substance use disorder
  • social impairment
  • impaired control
  • risky use
  • pharmacological indicators (tolerance and withdrawal).

You may not qualify if:

  • Patient with other psychatric disorders ex schizophrenia, mood disorder

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (2)

  • Yuodelis-Flores C, Ries RK. Addiction and suicide: A review. Am J Addict. 2015 Mar;24(2):98-104. doi: 10.1111/ajad.12185. Epub 2015 Feb 2.

    PMID: 25644860BACKGROUND

  • Webster LR. Risk Factors for Opioid-Use Disorder and Overdose. Anesth Analg. 2017 Nov;125(5):1741-1748. doi: 10.1213/ANE.0000000000002496.

    PMID: 29049118BACKGROUND

MeSH Terms

Conditions

Substance-Related Disorders

Interventions

Drug Screening Assays, Antitumor

Condition Hierarchy (Ancestors)

Chemically-Induced DisordersMental Disorders

Intervention Hierarchy (Ancestors)

Cytological TechniquesClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisInvestigative TechniquesDrug Evaluation, PreclinicalEvaluation Studies as Topic

Central Study Contacts

hebat allah hassan goda

CONTACT

01090200687hebagoda119@gmail.com

wageh abd elnaser

CONTACT

01227432194

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
residant doctor

Study Record Dates

First Submitted

October 25, 2021

First Posted

November 4, 2021

Study Start

December 1, 2021

Primary Completion

December 1, 2021

Study Completion

December 1, 2023

Last Updated

November 10, 2021

Record last verified: 2021-10